NutriDex

The Supplement Research Compendium

🌾

Arabinoxylan

Cereal hemicellulose (AXOS)

Cereal hemicellulose fiber (and its AXOS oligosaccharides) with EFSA-backed postprandial glucose-lowering and a reliable bifidogenic effect.

Evidence tier
Moderate
Research weight
Citations
8 verified / 8
Classification
Prebiotics & Fibers
What the evidence says. Several controlled trials; effects real but modest or context-dependent.

What is Arabinoxylan?

Arabinoxylan (Cereal hemicellulose (AXOS)) is a prebiotic fiber used for lowers post-prandial blood glucose and insulin responses — the basis for an efsa-authorized health claim at ~8 g of wheat-endosperm ax-rich fiber per meal. NutriDex grades the human evidence as Moderate. Arabinoxylan (AX) is the main soluble hemicellulose fiber of cereal grains such as wheat, rye, barley and psyllium; enzymatically shortened forms are called arabinoxylan-oligosaccharides (AXOS). Its best-supported effect is on glucose: a 2025 systematic review and meta-analysis of clinical and preclinical studies found AX significantly reduced postprandial glucose and insulin responses, and the EFSA authorizes a health claim that ~8 g of AX-rich fiber from wheat endosperm per meal lowers post-prandial glycaemia. Small randomized crossover trials in people with type 2 diabetes or impaired glucose tolerance also show lower fasting glucose, HbA1c and triglycerides, and human studies consistently show AXOS is bifidogenic and raises short-chain fatty acids (especially butyrate). Evidence is most robust for acute glycemic and microbiome endpoints; data on LDL cholesterol, weight and long-term clinical outcomes are thinner and less consistent, with trials generally small.

Purported Benefits

Lowers post-prandial blood glucose and insulin responses — the basis for an EFSA-authorized health claim at ~8 g of wheat-endosperm AX-rich fiber per meal
Improves longer-term glycemic control in type 2 diabetes and impaired glucose tolerance: small crossover RCTs report reduced fasting glucose, HbA1c, fructosamine and apolipoprotein B
Reliably bifidogenic — AXOS and AX increase fecal Bifidobacterium and butyrate-producing bacteria, raising short-chain fatty acid (SCFA) production
Can modestly lower fasting serum triglycerides in some trials (effect on LDL/total cholesterol is inconsistent and generally not significant)
Increases satiety hormones and lowers ghrelin response in some studies, which may support appetite control
As a fermentable soluble fiber, contributes to stool bulking and laxation, though dedicated constipation trials are limited

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Lowers postprandial glucose & insulin2025 meta-analysis (glucose iAUC SMD -0.41) and EFSA-authorized claim at ~8 g/meal; most robust AX endpoint. Moderate ↑ benefit · moderate 3
Improves longer-term glycemia (fasting glucose, HbA1c)Small crossover RCTs in T2D/IGT lowered fasting glucose, fructosamine, HbA1c; trials small (n=15) and few. Preliminary ↑ benefit · moderate 2
Prebiotic: bifidogenic, raises butyrate (AXOS)Multiple RCTs show AXOS raises fecal bifidobacteria/butyrate-producers and lowers p-cresol; well tolerated. Moderate ↑ benefit · moderate 3
Lowers fasting triglyceridesSmall crossover RCTs lowered triglycerides; LDL/total-cholesterol effects inconsistent and generally non-significant. Preliminary ↑ benefit · small 2

Dosing & Compounds

Typical Dose
For postprandial glucose: ~8 g of wheat-endosperm AX-rich fiber consumed as part of a carbohydrate meal (EFSA condition). Metabolic trials in diabetes/IGT used roughly 6-15 g/day of AX added to bread or muffins over 4-6 weeks. For a bifidogenic/prebiotic effect, AXOS has been effective from ~2.2 g/day up to ~10 g/day; tolerance studies support doses up to about 10 g/day. Best taken with cereal-based meals.
Active Compounds
AXOS ingredients (e.g. NAXUS / Comet Bio, BioActor AXOS) used in functional foods and supplementsWheat-endosperm arabinoxylan concentrates and wheat-bran/aleurone AX-rich fractionsAXOS-enriched (endoxylanase-treated) breads and cereal productsRice-bran arabinoxylan compound (e.g. MGN-3/BioBran, a different immunomodulatory product)Food sources: whole wheat, rye, barley, oats, psyllium husk, wheat and rice bran, and other whole-grain cereals

Safety & Cautions

Generally well tolerated. Because AX and especially AXOS are fermented in the colon, the main side effects are flatulence, bloating and abdominal discomfort, which are dose-dependent and tend to ease over time; doses around 10 g/day of AXOS are tolerated in healthy adults, with more gas at higher intakes. As fermentable fibers they can aggravate symptoms in some people with IBS or on a low-FODMAP diet (start low and increase gradually with adequate fluids). Like other viscous/bulking fibers, AX may slow or reduce absorption of co-ingested medications and minerals, so separate doses from medications by 2-4 hours. People with celiac disease or wheat allergy should avoid wheat-derived AX/AXOS products. Note that rice-bran arabinoxylan compound (MGN-3/BioBran) is a distinct immunomodulatory product and its claims should not be conflated with cereal AX/AXOS fiber. Those with diabetes on glucose-lowering drugs should monitor blood sugar. Educational only — always check with your doctor or pharmacist before combining Arabinoxylan with any medicine.

Key Studies

Systematic review and meta-analysis Systematic review & meta-analysis 2025 ✓ Full text
Across clinical studies, arabinoxylan significantly improved postprandial glycemic control: glucose iAUC (SMD -0.41; 95% CI -0.57 to -0.25), insulin iAUC (SMD -0.28; 95% CI -0.44 to -0.12) and glucose peak (SMD -0.52; 95% CI -0.80 to -0.25) versus control.
Regulatory health-claim opinion EFSA NDA Panel 2011 (ID 830) ✓ Source
EFSA concluded a cause-and-effect relationship between consumption of wheat-endosperm arabinoxylan and reduction of post-prandial glycaemic responses, with the claim conditioned on ~8 g AX-rich fibre (>=60% AX) per 100 g available carbohydrate per meal.
Randomized crossover trial (multi-omics) Benitez-Paez / Lappi multi-omics 2019 ✓ Full text
In overweight adults with metabolic-syndrome signs, 10.4 g/day AXOS induced a bifidogenic shift, increased butyrate-producing species and Prevotella, and altered microbial functional genes versus control.
Randomized placebo-controlled crossover RCT Cloetens et al. 2010 ✓ PubMed
In healthy subjects, 2.2 g/day of AXOS (avDP 9) for 3 weeks significantly increased faecal bifidobacteria and lowered urinary p-cresol, demonstrating prebiotic activity, while being well tolerated.
Randomized double-blind crossover RCT Walton et al. 2012 ✓ PubMed
In 40 healthy volunteers, AXOS-enriched bread (2.2 g AXOS) was well tolerated with no significant adverse GI effects versus control bread, supporting its use in functional bread products.
Randomized crossover RCT Hartvigsen et al. 2014 ✓ PubMed
In subjects with metabolic syndrome, test meals with concentrated arabinoxylan lowered acute post-prandial glucose and insulin responses compared with refined wheat, though longer-term whole-day effects were modest.
Randomized crossover RCT Lu et al. 2004 ✓ PubMed
In 15 adults with type 2 diabetes, AX-rich wheat fibre over two 5-week periods significantly lowered fasting and post-load glucose, serum fructosamine, triglycerides and apolipoprotein B versus control bread/muffins.
Randomized crossover RCT Garcia et al. 2006 ✓ PubMed
In subjects with impaired glucose tolerance, 6 weeks of 15 g/day arabinoxylan significantly reduced fasting serum glucose, triglycerides and apolipoprotein A-1 compared with placebo bread.

Common questions about Arabinoxylan

What is Arabinoxylan used for?

Arabinoxylan is most often taken for Lowers post-prandial blood glucose and insulin responses — the basis for an EFSA-authorized health claim at ~8 g of wheat-endosperm AX-rich fiber per meal, Improves longer-term glycemic control in type 2 diabetes and impaired glucose tolerance: small crossover RCTs report reduced fasting glucose, HbA1c, fructosamine and apolipoprotein B, Reliably bifidogenic — AXOS and AX increase fecal Bifidobacterium and butyrate-producing bacteria, raising short-chain fatty acid (SCFA) production, Can modestly lower fasting serum triglycerides in some trials (effect on LDL/total cholesterol is inconsistent and generally not significant). Cereal hemicellulose fiber (and its AXOS oligosaccharides) with EFSA-backed postprandial glucose-lowering and a reliable bifidogenic effect.

Does Arabinoxylan work — what does the evidence say?

Moderate evidence. Several controlled trials; effects real but modest or context-dependent. Arabinoxylan (AX) is the main soluble hemicellulose fiber of cereal grains such as wheat, rye, barley and psyllium; enzymatically shortened forms are called arabinoxylan-oligosaccharides (AXOS). Its best-supported effect is on glucose: a 2025 systematic review and meta-analysis of clinical and preclinical studies found AX significantly reduced postprandial glucose and insulin responses, and the EFSA authorizes a health claim that ~8 g of AX-rich fiber from wheat endosperm per meal lowers post-prandial glycaemia. Small randomized crossover trials in people with type 2 diabetes or impaired glucose tolerance also show lower fasting glucose, HbA1c and triglycerides, and human studies consistently show AXOS is bifidogenic and raises short-chain fatty acids (especially butyrate). Evidence is most robust for acute glycemic and microbiome endpoints; data on LDL cholesterol, weight and long-term clinical outcomes are thinner and less consistent, with trials generally small.

What is the typical dose of Arabinoxylan?

For postprandial glucose: ~8 g of wheat-endosperm AX-rich fiber consumed as part of a carbohydrate meal (EFSA condition). Metabolic trials in diabetes/IGT used roughly 6-15 g/day of AX added to bread or muffins over 4-6 weeks. For a bifidogenic/prebiotic effect, AXOS has been effective from ~2.2 g/day up to ~10 g/day; tolerance studies support doses up to about 10 g/day. Best taken with cereal-based meals.

Is Arabinoxylan safe? Any cautions or side effects?

Generally well tolerated. Because AX and especially AXOS are fermented in the colon, the main side effects are flatulence, bloating and abdominal discomfort, which are dose-dependent and tend to ease over time; doses around 10 g/day of AXOS are tolerated in healthy adults, with more gas at higher intakes. As fermentable fibers they can aggravate symptoms in some people with IBS or on a low-FODMAP diet (start low and increase gradually with adequate fluids). Like other viscous/bulking fibers, AX may slow or reduce absorption of co-ingested medications and minerals, so separate doses from medications by 2-4 hours. People with celiac disease or wheat allergy should avoid wheat-derived AX/AXOS products. Note that rice-bran arabinoxylan compound (MGN-3/BioBran) is a distinct immunomodulatory product and its claims should not be conflated with cereal AX/AXOS fiber. Those with diabetes on glucose-lowering drugs should monitor blood sugar.

How many studies support Arabinoxylan?

NutriDex cites 8 sources for Arabinoxylan, graded "Moderate".

Cite this page
APA

Peh, D. (2026). Arabinoxylan (Cereal hemicellulose (AXOS)): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/arabinoxylan

BibTeX
@misc{nutridex_arabinoxylan,
  author       = {Peh, Daryl},
  title        = {Arabinoxylan (Cereal hemicellulose (AXOS)): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/arabinoxylan},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances